Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Ozempic and Wegovy would no longer be covered by the state’s health insurance for low-income people under the governor’s ...

The Japanese company reported higher quarterly earnings, supported by its music and movie businesses. The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 ...